• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾功能和肾体积对常染色体显性多囊肾病患者颅内动脉瘤的影响。

Impact of kidney function and kidney volume on intracranial aneurysms in patients with autosomal dominant polycystic kidney disease.

机构信息

Department of Nephrology, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, 162-8666, Japan.

Clinical Research Division for Polycystic Kidney Disease, Department of Nephrology, Tokyo Women's Medical University, Tokyo, Japan.

出版信息

Sci Rep. 2022 Oct 27;12(1):18056. doi: 10.1038/s41598-022-22884-9.

DOI:10.1038/s41598-022-22884-9
PMID:36302803
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9613770/
Abstract

Presently, only personal or family history of intracranial aneurysm/subarachnoid hemorrhage (IA/SAH) has been established as a risk factor for IA in autosomal dominant polycystic kidney disease (ADPKD). This study aimed to verify the association between kidney function/volume and IAs in patients with ADPKD. This study included 519 patients with ADPKD. At baseline IA screening, the median age and estimated glomerular filtration rate were 44 years and 54.5 mL/min/1.73 m, respectively. Family IA/SAH history was confirmed in 18.1% of the patients, and 54.3% of the patients had hypertension. The IA point prevalence was 12.5%. During clinical follow up of 3104 patient-years, de novo IA was detected in 29 patients (0.93% patient-years). The IA period prevalence was 18.1% (median age, 60 years). Multivariable logistic regression demonstrated that total kidney volume (TKV) ≥ 1000 mL (odds ratio [OR] = 2.81), height-adjusted TKV ≥ 500 mL (OR = 2.81), Mayo imaging classification Class 1D-1E (OR = 2.52), and chronic kidney disease stages 3-5 (OR = 2.31) were significantly associated with IA formation. IAs in patients with ADPKD may be associated not only with general risk factors for IAs but also with declining kidney function and increased KV. Kidney disease progression may contribute to effective IA screening and treatment planning in patients with ADPKD.

摘要

目前,仅有颅内动脉瘤/蛛网膜下腔出血(IA/SAH)的个人或家族史被确定为常染色体显性多囊肾病(ADPKD)中 IA 的危险因素。本研究旨在验证 ADPKD 患者的肾功能/体积与 IA 之间的关联。本研究纳入了 519 名 ADPKD 患者。在 IA 筛查的基线时,中位年龄和估算肾小球滤过率分别为 44 岁和 54.5 mL/min/1.73 m。18.1%的患者有 IA/SAH 家族史,54.3%的患者患有高血压。IA 的现患率为 12.5%。在 3104 患者年的临床随访期间,29 名患者(0.93%患者年)新检出 IA。IA 的期间现患率为 18.1%(中位年龄 60 岁)。多变量逻辑回归显示总肾体积(TKV)≥1000 mL(比值比[OR] = 2.81)、身高校正的 TKV≥500 mL(OR = 2.81)、Mayo 影像学分类 1D-1E 级(OR = 2.52)和慢性肾脏病 3-5 期(OR = 2.31)与 IA 形成显著相关。ADPKD 患者的 IA 不仅可能与 IA 的一般危险因素相关,还可能与肾功能下降和 KV 增加相关。肾脏疾病的进展可能有助于对 ADPKD 患者进行有效的 IA 筛查和治疗计划。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984e/9613770/5e48c3919f85/41598_2022_22884_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984e/9613770/06acf1112245/41598_2022_22884_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984e/9613770/44cb764fc0fe/41598_2022_22884_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984e/9613770/5e48c3919f85/41598_2022_22884_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984e/9613770/06acf1112245/41598_2022_22884_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984e/9613770/44cb764fc0fe/41598_2022_22884_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984e/9613770/5e48c3919f85/41598_2022_22884_Fig3_HTML.jpg

相似文献

1
Impact of kidney function and kidney volume on intracranial aneurysms in patients with autosomal dominant polycystic kidney disease.肾功能和肾体积对常染色体显性多囊肾病患者颅内动脉瘤的影响。
Sci Rep. 2022 Oct 27;12(1):18056. doi: 10.1038/s41598-022-22884-9.
2
Factors associated with early-onset intracranial aneurysms in patients with autosomal dominant polycystic kidney disease.与常染色体显性多囊肾病患者早发性颅内动脉瘤相关的因素。
J Nephrol. 2024 May;37(4):983-992. doi: 10.1007/s40620-023-01866-8. Epub 2024 Feb 5.
3
Polycystic kidney disease among 4,436 intracranial aneurysm patients from a defined population.来自特定人群的4436例颅内动脉瘤患者中的多囊肾病
Neurology. 2017 Oct 31;89(18):1852-1859. doi: 10.1212/WNL.0000000000004597. Epub 2017 Oct 4.
4
Presymptomatic Screening for Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease.常染色体显性多囊肾病患者颅内动脉瘤的无症状筛查。
Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1151-1160. doi: 10.2215/CJN.14691218. Epub 2019 Jul 30.
5
Relationship between intracranial aneurysms and the severity of autosomal dominant polycystic kidney disease.颅内动脉瘤与常染色体显性多囊肾病严重程度之间的关系。
Acta Neurochir (Wien). 2017 Dec;159(12):2325-2330. doi: 10.1007/s00701-017-3316-8. Epub 2017 Sep 7.
6
Natural history of intracranial aneurysms in autosomal dominant polycystic kidney disease.常染色体显性多囊肾病患者颅内动脉瘤的自然史。
Neurol Neurochir Pol. 2017 Nov-Dec;51(6):476-480. doi: 10.1016/j.pjnns.2017.08.007. Epub 2017 Aug 18.
7
Cerebral Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Comparison of Management Approaches.常染色体显性多囊肾病相关的颅内动脉瘤:管理方法的比较。
Neurosurgery. 2019 Jun 1;84(6):E352-E361. doi: 10.1093/neuros/nyy336.
8
Clinical Factors Associated with the Risk of Intracranial Aneurysm Rupture in Autosomal Dominant Polycystic Kidney Disease.常染色体显性遗传多囊肾病患者颅内动脉瘤破裂风险的相关临床因素。
Cerebrovasc Dis. 2021;50(3):339-346. doi: 10.1159/000513709. Epub 2021 Mar 11.
9
Is Regular Screening for Intracranial Aneurysm Necessary in Patients with Autosomal Dominant Polycystic Kidney Disease? A Systematic Review and Meta-analysis.常染色体显性多囊肾病患者是否需要定期进行颅内动脉瘤筛查?一项系统评价和荟萃分析。
Cerebrovasc Dis. 2017;44(1-2):75-82. doi: 10.1159/000476073. Epub 2017 May 13.
10
Lack of impact of polycystic kidney disease on the outcome of aneurysmal subarachnoid hemorrhage: a matched case-control study.多囊肾病对动脉瘤性蛛网膜下腔出血预后无影响:一项配对病例对照研究。
J Neurosurg. 2020 Jul 3;134(6):1871-1878. doi: 10.3171/2020.4.JNS20544. Print 2021 Jun 1.

引用本文的文献

1
Differences in gut microbiome between autosomal dominant polycystic kidney disease with and without intracranial aneurysms.伴有和不伴有颅内动脉瘤的常染色体显性多囊肾病患者肠道微生物群的差异。
Sci Rep. 2025 Jul 7;15(1):24204. doi: 10.1038/s41598-025-08942-y.
2
Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances.常染色体显性多囊肾病:近期遗传学和临床进展概述
Ren Fail. 2025 Dec;47(1):2492374. doi: 10.1080/0886022X.2025.2492374. Epub 2025 Apr 23.
3
Microvascular aberrations found in human polycystic kidneys are an early feature in a Pkd1 mutant mouse model.

本文引用的文献

1
Germline Mutations for Kidney Volume in ADPKD.常染色体显性多囊肾病中肾脏体积的胚系突变
Kidney Int Rep. 2021 Dec 13;7(3):537-546. doi: 10.1016/j.ekir.2021.12.012. eCollection 2022 Mar.
2
Renal plasticity revealed through reversal of polycystic kidney disease in mice.通过逆转小鼠多囊肾病揭示肾脏的可塑性。
Nat Genet. 2021 Dec;53(12):1649-1663. doi: 10.1038/s41588-021-00946-4. Epub 2021 Oct 11.
3
A digest from evidence-based Clinical Practice Guideline for Polycystic Kidney Disease 2020.《2020年多囊肾病循证临床实践指南》摘要
在人类多囊肾中发现的微血管异常是Pkd1突变小鼠模型中的一个早期特征。
Dis Model Mech. 2025 Apr 1;18(4). doi: 10.1242/dmm.052024. Epub 2025 Apr 28.
4
Association of hyperphosphatemia with renal prognosis in patients with autosomal dominant polycystic kidney disease.常染色体显性多囊肾病患者高磷血症与肾脏预后的关系
Clin Exp Nephrol. 2025 Jan;29(1):75-82. doi: 10.1007/s10157-024-02568-6. Epub 2024 Sep 25.
5
Data driven approach to characterize rapid decline in autosomal dominant polycystic kidney disease.数据驱动方法分析常染色体显性遗传性多囊肾病的快速进展。
PLoS One. 2024 Jun 5;19(6):e0298484. doi: 10.1371/journal.pone.0298484. eCollection 2024.
6
Factors associated with early-onset intracranial aneurysms in patients with autosomal dominant polycystic kidney disease.与常染色体显性多囊肾病患者早发性颅内动脉瘤相关的因素。
J Nephrol. 2024 May;37(4):983-992. doi: 10.1007/s40620-023-01866-8. Epub 2024 Feb 5.
7
Cardiovascular Manifestations and Management in ADPKD.常染色体显性多囊肾病的心血管表现与管理
Kidney Int Rep. 2023 Aug 4;8(10):1924-1940. doi: 10.1016/j.ekir.2023.07.017. eCollection 2023 Oct.
8
Public support for patients with intractable diseases in Japan: impact on clinical indicators from nationwide registries in patients with autosomal dominant polycystic kidney disease.日本公众对疑难病症患者的支持:常染色体显性多囊肾病患者全国登记数据对临床指标的影响
Clin Exp Nephrol. 2023 Oct;27(10):809-818. doi: 10.1007/s10157-023-02372-8. Epub 2023 Jun 27.
Clin Exp Nephrol. 2021 Dec;25(12):1292-1302. doi: 10.1007/s10157-021-02097-6. Epub 2021 Sep 26.
4
Predicting liver cyst severity by mutations in patients with autosomal-dominant polycystic kidney disease.通过常染色体显性多囊肾病患者的基因突变预测肝囊肿严重程度。
Hepatol Int. 2021 Jun;15(3):791-803. doi: 10.1007/s12072-021-10176-9. Epub 2021 Apr 2.
5
Clinical Factors Associated with the Risk of Intracranial Aneurysm Rupture in Autosomal Dominant Polycystic Kidney Disease.常染色体显性遗传多囊肾病患者颅内动脉瘤破裂风险的相关临床因素。
Cerebrovasc Dis. 2021;50(3):339-346. doi: 10.1159/000513709. Epub 2021 Mar 11.
6
Intracranial aneurysms in renal transplant recipients with autosomal dominant polycystic kidney disease.常染色体显性多囊肾病肾移植受者的颅内动脉瘤
Pol Arch Intern Med. 2020 Dec 22;130(12):1111-1113. doi: 10.20452/pamw.15648. Epub 2020 Oct 15.
7
Prediction of Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease Using PKD1/PKD2 Mutations.利用PKD1/PKD2突变预测常染色体显性多囊肾病患者的肾脏预后
J Clin Med. 2020 Jan 5;9(1):146. doi: 10.3390/jcm9010146.
8
Intracranial aneurysms in patients receiving kidney transplantation for autosomal dominant polycystic kidney disease.常染色体显性多囊肾病患者接受肾移植术后的颅内动脉瘤。
Acta Neurochir (Wien). 2019 Nov;161(11):2389-2396. doi: 10.1007/s00701-019-04060-7. Epub 2019 Sep 9.
9
Presymptomatic Screening for Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease.常染色体显性多囊肾病患者颅内动脉瘤的无症状筛查。
Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1151-1160. doi: 10.2215/CJN.14691218. Epub 2019 Jul 30.
10
Screening for Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease.常染色体显性多囊肾病患者颅内动脉瘤的筛查
Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1242-1244. doi: 10.2215/CJN.02100219. Epub 2019 Jun 19.